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ABSTRACT
Because we observed increasing incidences over time, advancing age, higher estrogen levels, decreasing UVB (290-315 nm)
doses, or lower vitamin D3, and Human Papillomavirus hiding in immune-privileged sites of hair follicles play roles in melanoma,
we wondered if the majority of cancers might have similar carcinogenic drivers. To investigate this possibility, we performed
worldwide analysis of all sites but skin cancer over time (1955-2007), advancing age, and UVB doses for males and females with
all skin types and ages (0-85+) and in five age groups using IARC data. To investigate Human Papillomavirus’s role, we analyzed
the incidences of breast, prostate, and colon cancers in a developed country with European ancestry (New Zealand) having high
amounts of androgenic hair and a developing country with Asian ancestry (India) having low amounts of androgenic hair. To
potentially add epidemiology to the already established role of estrogen in cancer, we analyzed males and females in various
countries around the world using the incidence of breast cancer (> 70 yr.) as an established indicator of estrogen levels. The
analysis reveals cancer incidences are steadily increasing over time in developed but not developing countries regardless of skin
type. Only US white, but not black, breast, prostate, and colon cancer incidences in the oldest age group significantly decreased
with increasing UVB dose suggesting a role for vitamin D3. The data suggests the carcinogenic drivers in many cancers are
estrogen, increasing age (or reactive oxygen species), decreasing vitamin D3 levels, and persistence of Human Papillomavirus
infection in immune-privileged sites.
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1. INTRODUCTION
Cancer is the second leading cause of human death world-
wide. In 2015, there were 17.5 million new cancer cases and
8.7 million cancer deaths worldwide.[1] For men, prostate
cancer (1.6 million cases) was the most common; for women,
breast cancer (2.4 million cases) was the most common; for
both sexes, colon and rectum cancers (1.78 million) were
the third most prevalent cancers worldwide. Alarmingly, the
incidence of all cancers rose 33% in only one decade (2005-
2015); prostate cancer rose 66.1%, breast cancer rose 43%,
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and colon cancer rose 36.5%.
DNA mutations and genomic instability primarily cause
cancer. These alterations in the DNA can occur through
physical, chemical, or biological agents. For example, we
know cumulative doses of UV radiation (UVR; 280-400 nm)
increase the risk for getting non-melanoma skin cancer;[2]
estrogen[3, 4] and BRAC 1 and 2 mutations[5] increase the
risk for getting breast cancer; Human Papillomavirus (HPV)
infections cause genomic instability that increases the risk
for getting cervical[6] and oropharyngeal cancers.[7] UVB
radiation (280-315 nm) directly causes DNA damage as cy-
clobutane pyrimidine dimers, while UVA radiation (316-400
nm) indirectly causes oxidative DNA damage by creating re-
active oxygen species (ROS) that makes 8-oxo-dGuanine,[8]
which is later incorporated into the DNA leading to sub-
sequent mutations.[9] UVA radiation also causes oxidation
of cytosines leading to deamination and subsequent C→T
transition mutations.[10]
Besides DNA mutations and genomic instability, epigenetic
events can affect cancer formation via the production of
soluble factors like inflammatory cytokines, vitamin D3, es-
trogen, ROS, or methylation of DNA bases. For example, the
inflammatory cytokines produced by UVB-irradiated skin
and oral tissue cells[11] circulate systemically increasing the
risk for getting cervical, pharyngeal,[12] and many other can-
cers.[13] In contrast, UVB produces vitamin D3 in the skin[14]
that also circulates systemically and may counter the effects
of the inflammatory cytokines and possibly even decrease
the risk for getting some cancers.[15] UVA radiation cre-
ates ROS that can further contribute toward carcinogenesis
by activating HPV[16] and combined with estrogen cause
increased expression of HPV’s oncogenic proteins E6 and
E7[17] that immortalize cells by inactivating p53 and pRB,
respectively.[18] ROS synergistically increases the risk for
getting cancer when combined with estrogen, as shown in
a hamster kidney cancer model.[19] Estrogen has also been
declared a human carcinogen by the International Agency
for Research on Cancer (IARC)[20] because it increases the
risk for females getting cervical, breast, ovarian, and en-
dometrial cancers;[21] estrogen also increases the risk for
males getting breast[22] and prostate cancers.[23–25] Finally,
epigenetic methylation of cytosines from the virally-induced
APOBEC system results in deamination of cytosines cre-
ating driver mutations in the PIK3CA gene[26–28] found in
various cancers,[29] which are associated with HPV signature
mutations.[30]
We know high risk HPV’s (primarily 16 and 18) are defi-
nitely involved in cervical, pharyngeal, penile, anal, vaginal,
and vulva cancers[31] and recently meta-analysis suggests
HPV is probably involved in other cancers as well such
as lung,[32, 33] prostate,[34, 35] breast,[36] colon,[37] ovarian,[38]
bladder,[39] and non-melanoma skin cancer.[40] In addition,
HPV has been found in cancers like cutaneous malignant
melanoma,[41, 42] eye,[43] esophageal,[44] and stomach.[45, 46]
HPV may be the reason some cancers are recently increas-
ing over time like pancreas, liver, thyroid, and kidney,[47]
and is possibly involved in other cancers that have not yet
been discovered. Moreover, children, babies, and fetuses can
be infected with HPV because it can cross the placenta,[48]
which may explain the recent (1975-2012) 0.6%/year rise in
childhood cancers.[49] Persistent HPV infection is responsi-
ble for over 90% of cervical and anal cancers, around 70%
of vulvar, vaginal, and oropharynx cancers, and over 60%
of penile cancers the rates of which vary by race and eth-
nicity: Hispanics and blacks > whites > Asian and Pacific
Islanders.[50]
If a cancer is steadily increasing over time beyond what
genetic inheritance predicts, like cutaneous malignant
melanoma,[51, 52] that may indicate HPV infection is involved
because its incidence has been documented to be increas-
ing dramatically over recent decades in Europe[53] and in
the United States (US).[7] However, depending on the type
of cancer, the increasing incidence over time could be due
to the spread of other infectious diseases like herpesviruses
(EBV and KSHV), polyomaviruses (SV40, MCV, BK, and
JCV), hepadnaviruses (HBV), flaviviruses (HCV), defective
viruses (HDV), retroviruses (HTLV-I, HTLV-II, HIV-1, HIV-
2, HERV-K, and XMRV), and bacteria, like H. pylori, S.
typhi, S. bovis, Bartonella, and C. pneumonia, as well as
protozoa, like P. falciparum, and parasites like trematodes,
like S. haematobium, S. japonicum, S. mansoni, O. viverrini,
O. felineus, and C. sinensis.[54] In previous studies, we ana-
lyzed cutaneous malignant melanoma over time all over the
world[51] and also over personal UVB dose in Europe[52] and
found an exponential increase in the incidence from 1955 to
2007 for only people of European ancestry. We speculated
a viral infection like HPV might be involved because the
rate only began to increase significantly over time, and in-
creased with decreasing personal UVB dose only after 1960,
implying increasing time indoors causing low levels of vi-
tamin D3 may be promoting infection.[52] Vitamin D3 has
been gradually decreasing over several decades, as noted
by the increasing trend of its inversely related parathyroid
hormone.[55] Our recent analysis of melanoma incidences
around the world provided evidence that HPV persists in im-
mune privileged androgenic hair follicles where melanocytes,
keratinocytes, and stem cells reside.[51] In fact, HPV may be
able to hide in many other immune privileged sites through-
out the body: (fetus), brain, eye, mucosa, gut, testis, liver,
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skin, lymph node, and tumors.[56]
We reasoned that if the majority of cancers are actually
caused or promoted by HPV, then we would expect to see
“fingerprints” of its involvement such as increasing incidence
over time, age, estrogen (comparing male and female inci-
dences over age), and decreasing UVB doses (lower vitamin
D3 levels). To test this hypothesis, we used IARC data to
perform a worldwide analysis of all sites but skin cancer over
time (1955-2007), advancing age, and UVB doses for males
and females of all skin types and ages (0-85+) and in five
age groups (0-14, 15-29, 30-49, 50-69, and 70-85+). The
advantage of using the extensive IARC dataset, is that it is
a cancer registry of all cancers reported, and no sampling
(or the associated statistics) is required or appropriate. A
second advantage of the IARC dataset, is that, although rich
and extensive, it has not been extensively used in analyses
as presented here. The primary approach utilized here is to
examine, through regression, the relationship in variables
under study in different regions in the world, which differ in
aspects in the variables above – especially skin type and UV
dose. In order to discover which cancers might be driving the
increase over time, we analyzed the cancers with the high-
est incidences in males and females (breast, prostate, and
colon) in a developed country (New Zealand) with European
ancestry and high amounts of androgenic body hair and in
a developing country (India) with Asian ancestry and low
amounts of androgenic body hair. To uncover the role of es-
trogen levels in many populations worldwide, we compared
males and females over advancing age and used the highest
incidence of breast cancer, which occurs over 70 yr., as an in-
dicator of estrogen levels. We also analyzed five age groups
of male and female breast, prostate, and colon cancers over
UVB dose for whites and blacks in the US to see if vitamin
D3 affects the risk.
2. MATERIALS AND METHODS
2.1 Analysis approach for all sites but skin cancer in-
cidences by sex, age, and countries’ skin type over
time (1955-2007)
We analyzed the national average, or aggregated the regional
population-based cancer registry data to get the national av-
erage, of the cancer incidences from IARC.[57] We used the
male and female age-standardized ‘all sites but skin’ (C00-
96bC44) cancer incidence rates (ASR) per 100,000 world
standard population for either all ages (0-85+) or five age
groups (0-14, 15-29, 30-49, 50-69, 70-85+) at 5-year interval
midpoints over time from 1955 to 2007 and the country’s,
state’s, regions’, or territories’ average UVB dose. We pre-
viously described the Fitzpatrick skin type[58] designations
for the populations in the different countries, the latitudes
and UVB doses used, and the details of the method of analy-
sis.[12, 51, 52]
Quality control involved an assessment of the validity, com-
pleteness, and comparability of the incidence data, the details
of which IARC provides online.[57] The IARC cancer inci-
dence data includes all tumor stages, thicknesses, histological
subtypes, and body site locations. We analyzed 60 countries
around the world whenever they began collecting data until
2007, but note that some countries did not collect data during
certain time intervals between 1955 and 2007.
The only country added into this analysis that was not in-
cluded in our previously published studies[51, 52] is Thailand
where we analyzed over time, advancing age, and UVB doses
for skin type III-IV populations in Bangkok (13.8◦N), Chi-
ang Mai (18.8◦N), Chonburi (13.4◦N), Khon Kaen (16.4◦N),
Lampang (16.4◦N), and Songkhla (7.2◦N).
2.2 Analysis of specific cancers for all ages over time in
New Zealand and India: breast, prostate, and colon
We analyzed specific cancers known to have the highest inci-
dences in males and females worldwide to see which ones
were increasing or decreasing over time and causing the ‘all
sites but skin’ cancer incidence changes we observed in the
overall cancer analysis shown in Figure 1. Using IARC
data,[57] we analyzed the age-standardized cancer incidence
rates (ASR) per 100,000 world-standard population at the
5-year interval midpoint in 2005 (2003-2007) for males and
females of all ages (0-85+) in New Zealand and India for
three specific cancers, breast (C50), prostate (C61), and colon
(C18), and display the results in Figure 2.
2.3 Analysis over the advancing age of the individual
In Figure 3, we display the age-standardized cancer inci-
dence rates (ASR) per 100,000 world-standard population at
the 5-year interval midpoint in 2005 (2003-2007) over the
advancing age of males or females based on the average age
of each age group. To plot the data over the advancing age
of the individual in the five age groups 0-14, 15-29, 30-49,
50-69, 70-85+, we used 7, 22, 40, 60 and 80 yrs. respectively.
2.4 Analysis of breast cancer incidences of the older (70-
85+) males and females by countries’ skin type
Using IARC data,[57] we also analyzed the age-standardized
breast (C50) cancer incidence rates (ASR) per 100,000 world-
standard population at the 5-year interval midpoint in 2005
(2003-2007) by the country’s, state’s, regions’, or territo-
ries’ skin type for males and females in the oldest age group
(70-85+) and display the data in Figure 4.
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2.5 Analysis of specific cancers by age group over
UVB dose for whites and blacks in the US: breast,
prostate, and colon
To see if UVB dose affects the incidence of some cancers, we
analyzed the US regional population-based cancer registry
incidences in each state with available data for the white
and black, male and female age-standardized breast (C50),
prostate (C61), and colon (C18) cancer incidence rates (ASR)
per 100,000 world standard population for five age groups
(0-14, 15-29, 30-49, 50-69, 70-85+) using IARC data.[57] We
used the 5-year interval midpoint for the 2005 data to ana-
lyze each cancer over estimated residential UVB dose using
the population weighted latitude for each state as previously
described.[12, 52] This equation is based on actual measure-
ments of people’s outdoor UVB doses and that planar dose
was changed to an estimated whole body dose using cylinder
geometry at all angles.
Briefly the equation is: UVB dose = -280X + 22,000 where
X is the latitude.
3. RESULTS
To search for potential patterns and possible similarities and
differences between cancer incidences of all the countries
populations with different skin types and ancestry, we ana-
lyzed the incidences of all sites but skin cancer for males and
females in all age groups (0-85+) in almost every country
around the world (see Figure 1). We found the incidence
of all sites but skin cancer is only significantly increasing
in a steady manner over time in certain countries shown in
the top four panels, except Italy (see Table 1 for p values),
while it is either stable or decreasing slightly in the other
countries shown in the bottom two panels. The countries in
the bottom two panels do not have significant changes over
time as shown by the US Hispanic females in the last row
of Table 1 (results for the other countries not shown). The
male and female populations with the highest incidences in
countries (populations) with increasing incidences of all sites
but skin cancer over time are the US (blacks > whites > His-
panic males only), Australia, New Zealand, Canada, Spain,
Europe, Israel, and Japan. The male and female populations
of countries with stable incidences of all sites but skin cancer
over time are Italy, Africa, and South America, and those
with slightly decreasing incidences are China, Thailand, and
India.
Note that males always have noticeably higher incidences
than females but only in the developed countries with pri-
marily European-ancestry populations that have increasing
incidences over time, not in the developing countries with
other ancestry populations that have stable or decreasing
incidences (compare the males in the left panels with the
females in the right panels). The only exception is the US
Hispanics that have males with higher incidences that are
increasing over time (left middle panel), while the females
have lower incidences that are not increasing over time (right
bottom panel and see Table 1 for insignificant Hispanic Fe-
males p value). Black males have the highest incidence of
all sites but skin cancer followed by white (left top panel)
and Hispanic males (left middle panel) in the US. Although
Africa has a black population, it has a mixture of other popu-
lations that include but are not limited to Arabs, Egyptians,
Berbers, Moors, Mulatoes, Bantu, Semitic, and many oth-
ers.[59] Statistical analysis reveals all the males and females
in the countries displayed in the top four panels of Figure 1
have significant increases over increasing time, except the
males and females in Italy (see Table 1).
Table 1. The significance of increasing cancer incidence
over time for males and females from 1965 to 2005 in
various countries around the world shown in the top four
panels of Figure 1; including one example p value for US
Hispanic females from the bottom two panels showing no
significance
 
 
Country/Gender R2 p values 
US Black males 0.776 .00385 
US White males 0.908 2.06 × 10-5
Australia males 0.921 6.23 × 10-4
New Zealand males 0.931 4.34 × 10-4
Canada males 0.973 1.52 × 10-7
US White females 0.926 8.62 × 10-6 
US Black females 0.894 3.86 × 10-4 
New Zealand females 0.839 .00374 
Australia females 0.937 3.47 × 10-4 
Canada females 0.972 1.76 × 10-7 
Italy males 0.464 .0920 
Spain males 0.988 5.55 × 10-7 
Europe males 0.982 2.70 × 10-8 
Israel males 0.865 2.74 × 10-4 
Japan males 0.921 1.12 × 10-5 
US Hispanic males 0.851 4.00 × 10-4 
Israel Females 0.792 .00129 
Italy Females 0.189 .330 
Europe Females 0.952 1.50 × 10-6 
Spain Females 0.937 8.08 × 10-5 
Japan Females 0.857 1.23 × 10-4 
US Hispanic Females 0.134 .332 
 
Then we analyzed the worlds’ top cancer incidences of males
and females to know if the cancers with some of the highest
incidences in males and females, i.e., breast, prostate and
colon, are responsible for the observed increasing trend over
time. Because we found all cancers but skin are increas-
ing in people of European ancestry while they are stable or
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decreasing slightly in people of Asian ancestry like the east-
ern Indians, Chinese, and Thai, we analyzed people in New
Zealand and compared their values to people in India. The in-
cidence of breast cancer is significantly increasing over time
for females in New Zealand (see Table 2) while it is stable
over time for females in India (see Figure 2, top panel). Note
that the incidence of male breast cancer is extremely rare
and unnoticeable if all ages are analyzed (0-85+) because the
primary incidence occurs over the age of 70. The incidence
of prostate cancer is significantly increasing over time for
males in New Zealand (see Table 2), while it is decreasing
slightly over time for males in India (see Figure 2, middle
panel). The incidence of colon cancer is increasing slightly,
but not significantly (see Table 2), over time for males and
females in New Zealand and is decreasing slightly over time
for males and females in India (see Figure 2, bottom panel).
Table 2 shows only the New Zealand female breast and male
prostate cancers are significantly increasing over time, while
colon cancer is not. Moreover, no significant increase occurs
with Indian female breast cancer or either Indian or New
Zealand male or female colon cancer. The incidence of colon
cancer is significantly decreasing in the Asian-ancestry pop-
ulation of eastern Indians and may reflect their preference
for spices like turmeric, which is known to be an anti-cancer
agent. Breast, prostate, and colon cancers comprise ≥ 25%
of all sites but skin cancer and are apparently helping to
drive the upward trend over time in developed countries with
primarily European-ancestry populations. We also saw sig-
nificant increases in male and female thyroid and liver cancer
incidences in the US (results not shown).
Figure 1. Age-standardized incidences of all sites but skin cancer cases per 100,000 people over time (1965-2005) for
males and females 0-85+ years old in various countries around the world whose people have primarily Fitzpatrick skin type
I-III (white), III-IV (Asian and Hispanic), IV-V (Italian, Israeli, Indian) and V-VI (blacks). Top left panel (males): US
Black, US White, Australia, New Zealand, and Canada. Top right panel (females): US White, US Black, New Zealand,
Australia, and Canada. Middle left panel (males): Italy, Spain, Europe, Israel, Japan, and US Hispanic. Middle right panel
(females): Israel, Italy, Europe Spain, and Japan. Bottom left panel (males): China, South America, Africa, Thailand, and
India. Bottom right panel (females): US Hispanic, South America, China, Africa, Thailand, and India.
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Table 2. P values for the incidence of male and female colon, breast, and prostate cancers over time (1965-2005) in New
Zealand (European Ancestry) and India (Asian Ancestry)
 
 
 R2 p Values Slope Comments 
Breast cancer incidence over time     
NZ Females 0.924 3.72 × 10-5 0.950 Pos. Slope *** 
Indian Females 0.413 .0619 0.0859 Pos. Slope NS 
NZ Males 0.336 .102 0.0039 Pos. Slope NS 
Indian Males 0.718 .00394 0.0024 Pos. Slope ** 
Prostate cancer incidence over time  
NZ Males 0.689 .00560 1.87 Pos. Slope * 
Indian Males 0.434 .0534 -0.0546 Neg. Slope NS 
Colon cancer incidence over time  
NZ Male 0.505 .0320 0.160 Pos. Slope * 
NZ Female 0.163 .281 0.0687 Pos. Slope NS 
India Male 0.609 .0131 -0.0515 Neg. Slope * 
India Female 0.613 .0126 -0.0428 Neg. Slope * 
 *p < .05; **p< .005; ***p < .0005; NS: not significant; Pos. Slope: positive slope or incidence increases over time; Neg. Slope: negative slope or incidence decreases over time. 
 
Figure 2. Age-standardized incidences of breast, prostate, and colon per 100,000 people over time (1965-2005) for males
and females 0-85+ years old in New Zealand (NZ) with primarily European-ancestry Fitzpatrick skin type I-III (white) or
India with primarily Asian-ancestry Fitzpatrick skin IV-V (brown). Note that the European-ancestry cancer incidences are
always higher than the Asian-ancestry cancer incidences.
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We further analyzed the populations of the countries by five
age groups (0-14, 15-29, 30-49, 50-69 and 70-85+) over time
and over UVB dose (unpublished results). We observed a
significant increase only in the oldest age group (70-85+)
between the incidence of all sites but skin cancer and time
for European ancestry populations. In addition, we also ob-
served a decrease in the incidence of all sites but skin cancer
with increasing UVB dose but only for people in developed
countries with primarily European ancestry. Moreover, we
observed a significant correlation between decreasing cancer
incidence and increasing UVB dose for Thai and Indian fe-
males in the next oldest age group (50-69) and an opposite
correlation for African males and females, or decreasing can-
cer incidence with decreasing UVB dose (results not shown).
To learn how cancer changes over the advancing age of males
and females around the world, we analyzed the populations
of most of the countries that have increasing incidences over
time (see Table 3) and compared them to populations of
most of the countries that have stable or slightly decreasing
incidences over time (see Table 3) and depicted the results
in Figure 3A and B, respectively. We observe a noticeable
increase in the female incidence of all cancers but skin be-
tween the ages of 20 and 40 yrs. compared to the males in the
same age range (see Figure 3A) but only when the incidence
increases over time (see Table 3). Although slightly higher
for females, the all sites but skin cancer incidence does not
noticeably differ between the sexes when the incidence is
stable or decreasing over time (see Figure 3B). Table 3 shows
that females between 20 and 49 yrs. of age have almost twice
the incidence as males, while males have almost twice the
incidences as females over the age of 49. The incidence of all
sites but skin cancer increases with age independent of sex
or ethnicity and whether or not the incidence is increasing
(see Table 3) or stable/decreasing (see Table 3) over time.
Table 3. All sites but skin cancer incidences for the five age groups used in the UVB dose analysis; top portion is for the
four panels of Figure 1 with increasing cancer incidences over time (also plotted by age group in the top panels of Figure 3);
bottom portion is the bottom two panels of Figure1 with stable or decreasing cancer incidences over time (also plotted by
age group in the bottom panels of Figure 3)
 
 
Age group 0-14 0-14 15-29 15-29 30-49 30-49 50-69 50-69 70-85+ 70-85+ 
Gender Males Females Males Females Males Females Males Females Males Females 
Country           
US (Blacks) 14 13 25 33 156 233 1,441 892 3,008 1,651 
US (Whites) 17 15 35 42 149 250 1,217 901 2,949 1,740 
Australia 16 14 40 38 160 243 1,195 825 3,183 1,604 
Italy 18 15 41 42 138 247 1,087 767 2,920 1,375 
US (Hispanics) 16 14 30 30 107 203 913 698 2,274 1,386 
Average 16 14 34 37 142 235 1,170 816 2,867 1,551 
China 11 8 16 18 128 148 837 562 2,125 1,078 
South America 15 12 26 27 92 183 712 579 2,129 1,161 
Thailand 12 9 17 22 89 146 488 405 1,173 678 
Africa 19 13 25 31 127 197 454 498 1,120 673 
India 9 6 12 14 65 108 358 346 676 446 
Average 13 10 19 22 100 156 570 478 1,445 807 
 
Because we found US blacks have a higher incidence of
all sites but skin cancer than US whites have (see Figure 1)
and they are reported to have higher estrogen but not testos-
terone levels,[60] we analyzed male breast cancer that has the
highest, and most reliable, incidences in the oldest age group
(70-85+) as an indicator of estrogen levels in men (see Figure
4A, B and C). We did this because, similar to females, male
breast cancer incidence is also dependent on estrogen;[22]
to increase reliability of this rarely occurring cancer in men
we used the oldest age group because they have the highest
incidences. We found the incidence of male breast cancer
was highest in US blacks (9.8) and Israelis (10.8) followed
by Africans (7) and US whites (6.4) followed by Canadians
(6). The incidence of breast cancer, and presumably levels
of estrogen in males shown in Figure 4A, B, and C corre-
lates fairly well with the male incidences of all sites but skin
cancer shown in Figure 1. Blacks in the US have a higher
incidence of male breast cancer than US whites (and Canadi-
ans), which correlates well with the incidences of all sites but
skin cancer in males, except Australia and New Zealand that
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appear to be somewhat lower than we would predict based on
the results in Figure 1. The incidence of male breast cancer
shown in Figure 4B correlates well with those shown in the
middle two panels of Figure 1 except Israel (10.8) which
is somewhat higher than predicted, while Japan (2.1) and
Hispanics in the US (3.3) are lower than predicted based on
their incidences of all sites but skin cancer. The incidences
of male breast cancer in Figure 4C correlates well with the
incidence of all sites but skin cancer shown in the bottom two
panels of Figure 1, except Africans (7) appear higher than
predicted. The incidence of breast cancer in older females
(70-85+) shown in Figure 4D, E and F correlates extremely
well with the incidence of all sites but skin cancer for fe-
males shown in Figure 1 except for the slightly higher levels
in Canada (see Figure 4E).
Figure 3. Cancer incidence over the advancing age of the individual in 2005 (males on left, females on right): A) from
Figure 1’s Top and Middle Panels with increasing incidences over time (see Table 3A); B) from Figure 1’s Bottom Panels
with Stable or Decreasing incidences over time.
Figure 4. Age-standardized incidences in 2005 of male and female breast cancer cases for 70-85+ age group per 100,000
people as an indicator of estrogen levels of the different skin types around the world according to IARC data. Males: A) US
Blacks, US Whites, Australia, New Zealand, Canadian; B) Italy, Spain, Europe, Israel, Japan, US Hispanics; C) China,
South America, Africa, Thailand, India. Females: D) US Whites, US Blacks, New Zealand, Australia, Canada; E) Israel,
Italy, Europe, Spain, Japan; F) US Hispanic, South America, China, Africa, Thailand, India.
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To know if vitamin D3 plays a role in developed countries
with European-ancestry populations (indoor workers), we
analyzed breast, prostate and colon cancers over UVB dose
for white and black males and females in the US (2005).
The incidence of breast (see Table 4, Figure 5A, top panels),
prostate (see Table 4, Figure 5A bottom panels), and colon
(see Table 4C, Figure 5B) cancers all significantly decrease
with increasing UVB dose (negative slope) exclusively in the
oldest white population (70-85+). Additionally, breast and
prostate cancers, but not colon, have significant decreases
with increasing UVB dose (negative slope) in the next oldest
age group (50-69), and female breast cancer is also signifi-
cant in the middle-aged, age group (30-49; negative slope).
Note that only the US white, but not the black, population has
significant decreases in their cancer incidences with increas-
ing UVB. Because we only see a significant effect in whites
and not in blacks, a clear UVB effect is evident because the
melanin in the black skin absorbs the UVB impeding its’
penetration and consequently the biological effects. This sig-
nificance in the oldest age group of whites but not blacks may
be due to the white population’s higher vitamin D3 status
and consequent better immune response.
Table 4. Breast, Prostate and Colon cancer incidence of white and black females in the US (2005) for the older age groups,
30-49, 50-69 and 70-85+
 
 
 Age Group R2 p Values Slope Comments 
 30-49 0.207 .015 -.00299 Neg. Slope * 
White Female Breast 50-69 0.203 .016 -0.00555 Neg. Slope * 
 70-85+ 0.492 3.2×10-7 -0.0153 Neg. Slope *** 
 30-49 0.069 .168 0.00235 Pos. Slope NS 
Black Female Breast 50-69 0.001 .882 0.00056 Pos. Slope NS 
 70-85+ 0.025 .415 -0.0050 Neg. Slope NS 
 30-49 0.05 .146 -0.0003 Neg. Slope NS 
White Male Prostate 50-69 0.278 2.37 × 10-4 -0.0162 Neg. Slope *** 
 70-85+ 0.416 9.10 × 10-4 -0.0300 Neg. Slope *** 
 30-49 0.127 .058 -0.0018 Neg. Slope NS 
Black Male Prostate 50-69 0.015 .530 -0.0086 Neg. Slope NS 
 70-85+ 0.001 .584 0.0141 Pos. Slope NS 
 30-49 0.074 .041 0.000190 Pos. Slope * 
White Female Colon 50-69 0.050 .246 0.000786 Pos. Slope NS 
 70-85+ 0.613 5.17×10-7 -0.0131 Neg. Slope *** 
 30-49 0.145 .042 0.000404 Pos. Slope * 
Black Female Colon 50-69 0.050 .241 0.00161 Pos. Slope NS 
 70-85+ 0.008 .635 -0.00280 Neg. Slope NS 
 30-49 0.166 .028 0.000396 Pos. Slope * 
White Male Colon 50-69 0.104 .089 0.00189 Pos. Slope NS 
 70-85+ 0.273 .0037 -0.00979 Neg. Slope ** 
 30-49 0.168 .027 0.00101 Pos. Slope * 
Black Male Colon 50-69 0.097 .100 0.00462 Pos. Slope NS 
 70-85+ 0.000 .982 -0.000149 Neg. Slope NS 
 *p < .05; **p <.005; ***p < .0005; NS: not significant; Pos. Slope: positive slope or incidence increases with increasing UV; Neg. Slope: negative slope or incidence decreases with increasing UV. 
 
4. DISCUSSION
The data suggests the major carcinogenic drivers in many
cancers are estrogen, increasing age (ROS), and decreasing
vitamin D3 levels, which is due to more time spent indoors is
responsible for the persistence of HPV infection in immune
privileged androgenic hair follicles. The analysis reveals
major differences in the temporal cancer incidence trends
between developed countries (increasing steadily over time)
with European ancestry populations and developing countries
(stable to decreasing over time) with other ancestry popu-
lations regardless of skin type. This may reflect persistent
HPV infection of immune-privileged androgenic body hair
because European-ancestry populations have significantly
more than Asian-ancestry populations.[51] HPV is activated
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by ROS,[16] which can be produced during pheomelanin syn-
thesis in red and blond hair, unlike eumelanin synthesis in
black hair, or irradiation with UVA, or visible light down
the hair shaft of white hair, may cause excessive release of
virions systemically fueling carcinogenic events in distant
sites. Only people of European ancestry have pheomelanin
synthesis and they also have the most androgenic hair where
HPV can hide and be stimulated by estrogen.
Figure 5. Age-standardized incidences in 2005 of breast, prostate and colon cancer cases per 100,000 people by age group
(15-29, 30-49, 50-69, and 70-85+) and skin color over UVB dose in the US: A) female white and black breast cancer (top
two panels) and male white and black prostate cancer (bottom two panels); B) female white and black colon cancer (top two
panels) and male white and black colon cancer (bottom two panels). Note that we omitted the 0-14 yr. and 15-29 age
group’s data because most of the values were either zero or close to it.
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We obtained the first line of evidence that estrogen plays a
major role in all cancers from US black males who have a
significantly higher incidence of all cancers (but skin) than
US white males, which are steadily increasing over time
(see Figure 1), because they are known to have significantly
higher estrogen levels than white males.[60] We found more
evidence supporting a role for estrogen in all cancers by com-
paring male and female incidences especially between the
ages of 20 and 40. We found females, who have higher estro-
gen levels than males during that time of life, have noticeably
higher incidences of all cancers than males, particularly in
developed countries with European ancestry (see Figure 3A
and Table 3). That data also shows males have much higher
incidences than females over the age of 49 when they have
2-3 times higher estrogen levels than females.[61] Unlike
females whose estrogen levels decrease with age, male’s es-
trogen levels increase with age, which may explain why they
have significantly higher cancer incidences over age 69 (see
Figures 3, 5, and 6). Further evidence suggesting estrogen
is involved in many cancers can be seen in Figures 4A-C,
where male breast cancer serving as an indicator of estrogen
levels in men,[22] displays very good agreement with the inci-
dence levels of all sites but skin cancer seen in Figure 1. The
incidence of female breast cancer is in excellent agreement
with their incidences of all sites but skin cancer. Moreover,
the observed seasonality of many cancers[62–67] might reflect
the hormonal seasonal fluctuations of estrogen.[68, 69] Thus,
our findings add epidemiological support to the already ex-
isting biochemical evidence obtained from birth control pills
and hormonal replacement therapy in females suggesting a
carcinogenic role for estrogen[20] in many cancers of both
sexes.
If we assume estrogen levels have remained stable in all
populations over time, then it is not the reason why can-
cers have been steadily increasing over recent decades (see
Figure 1). To know if the top occurring cancers are all in-
creasing over time or which of those might be contributing
toward the steady increase; we analyzed some of the high-
est occurring cancer incidences in both males and females:
breast, prostate, and colon cancers (see Figure 2). We found
only the cancer incidences in developed countries primarily
of European ancestry (see Figure 1), as noted by the New
Zealand profiles compared to the developing country with
eastern Indian profiles, are steadily increasing over time and
they are also affected by vitamin D3 (breast and prostate).[15]
However, when we analyzed all cancer incidences over UVB
dose, we did not find significant support for a role for vita-
min D because the slope of the line was not significant with
UVB dose for most age groups except the oldest (results
not shown). While almost 20 cancers appear to decrease
with decreasing UVB dose or increasing vitamin D levels,[15]
some cancers increase with increasing UVB[12] so that a mix-
ture of these cancers might obscure a relationship with UVB
dose. For example, the incidence of cervical or pharyngeal
cancers increase with increasing UVB dose in the US only
in whites, and not blacks, presumably from inflammatory
cytokine production and the fact that these cells apparently
lack the vitamin D receptor and corresponding apoptotic
mechanism.[12]
Conversely, the incidence of cutaneous malignant melanoma
increases with decreasing UVB dose in Europe, especially
in Italy, and these cells have the vitamin D receptor.[52]
Melanoma is an excellent example of a cancer that shows
increasing incidence with decreasing UVB dose (and pre-
sumably decreasing vitamin D levels), especially after 1960.
Other cancers reported to increase with decreasing UVB
are lung, gastric, liver, colon, breast, prostate, endome-
trial, esophageal, bladder, head and neck, leukemia, ovar-
ian, pancreatic, pleura, rectal, thyroid, and non-Hodgkin’s
lymphoma.[15] We found breast, prostate and colon cancers
decrease with increasing UVB dose (or increasing latitude),
which agrees with others who found breast,[70] prostate[71]
and colon[72] cancers decrease with increasing UVB dose,[73]
decreasing latitude[74] or increasing vitamin D3.[75] We ex-
panded on those findings by analyzing the different skin types
in five age groups to find only the whites, but not the blacks,
oldest age group (70-85+) have significant negative slopes.
This indicates increasing UVB significantly decreases the
incidences of breast, prostate, and colon cancers presum-
ably from increasing levels of vitamin D3 and its positive
effects on biological systems like the immune response, gene
regulation, and inducing apoptosis of damaged cells.
So why have cancer rates been increasing steadily over time
only in developed countries? Some scientists think the in-
creasing incidence over time of all sites but skin cancer in
developed countries is due to increasing life expectancy, red
meat consumption, obesity, or exposure to chemical pollu-
tants. However, the increasing life expectancy in Japan has
outpaced the US since 1965 while their all sites but skin
cancer rates have been lower than the US over recent decades
(see Figure 1). Moreover, China also had a steady increase
in their life expectancy since 1965[76] but their all sites but
skin cancer rates have been decreasing over time (see Fig-
ure 1). Possibly the increasing consumption of red meat
over time might explain the increase in the incidence of can-
cer, but Japan and China have about the same low level red
meat consumption (about half the US) while the former has
increasing and the latter has decreasing cancer rates over
time.[77] Next the increasing obesity levels in developed and
lately developing countries also does not explain the increas-
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ing incidence of cancers over time because the rates of type 2
diabetes, an indicator of obesity, has increased dramatically
(about tenfold) in China from 1980 to 2008[78] while their
all sites but skin cancer levels have steadily declined during
that time frame (see Figure 1). Finally, increasing exposure
to industrialized pollutants are apparently not major carcino-
genic drivers because we observe an increasing incidence of
all cancers with increasing age in all countries worldwide
regardless if they are developed or developing (see Figure
3A and B and Table 3). Thus, increasing life expectancy,
red meat consumption, obesity, or exposure to industrialized
chemical pollutants does not explain the steadily increasing
incidence of all sites but skin cancer over recent decades.
One reasonable explanation for the steadily increasing in-
cidences of all sites but skin cancer over time in primarily
developed countries might be because these countries have
European ancestry populations with the most androgenic
body hair to harbor HPV.[51] European ancestry populations
increased indoor work and sun protection behaviors over
recent decades resulting in decreasing vitamin D3 levels, as
noted by the steady increase in its inversely related parathy-
roid hormone.[55] We know low levels of vitamin D3 fuel
persistent HPV infection[79] that has been steadily increasing
over recent decades in developed countries in Europe[53] and
in the US.[7] Moreover, all cancer incidences probably in-
crease over the advancing age of the individual because their
ability to make vitamin D3 decreases with increasing age
due to thinning of the epidermis[80] and exposure to higher
ROS levels, as shown by the shutdown of melanin synthesis
in hair turning it white.[81] Decreasing vitamin D3 levels and
increasing ROS with advancing age along with male estro-
gen levels that are 2-3 times higher than females over the
age of 49 might explain why all cancer incidences increase
with increasing age and steadily increase with advancing
age of males (see Figures 3A and 3B and values in Table
3). Intriguingly, lower levels of vitamin D lead to higher
levels of estrogen in a dose dependent manner,[82] so that
estrogen might have actually been slowly increasing over
recent decades in only developed countries where most peo-
ple work indoors. Lower cancer incidences in Asians and
other populations compared to European populations might
be from outdoor work leading to good vitamin D3 levels and
the fact that they primarily synthesize eumelanin (black hair),
which absorbs ROS, rather than pheomelanin (red and blond
hair) that produces ROS, so that ROS do not activate HPV
and cause increased release of its virions.
Estrogen combined with ROS synergistically increases the
incidence of cancer[19] and synergizes with HPV.[83] Estro-
gen is responsible for the onset, persistence, and malignant
transformation of cervical cells[84] by stimulating oncogenic
expression of HPV’s E6 and E7 proteins promoting viral
proliferation[17] and driving cells through the cell cycle.[85]
Additionally, ROS activates HPV[16] and its E6 protein can
in turn cause production of more ROS and DNA damage.[86]
The E2 protein of HPV also results in production of ROS
by interacting with the cells’ mitochondria[87] creating ox-
idized cytosines that can spontaneously deaminate and be-
come thymines. Cytosine to thymine transition mutations
can also occur via viral activation of the APOBEC system
resulting in epigenetic methylation and deamination of cy-
tosines. These epigenetic methylations are predominately
at NpCpG trinucleotide sites and are signature mutations
of most cancers.[29] APOBEC3B-mediated cytosine deam-
inations creating C→T (or G) mutations in phosphatidyli-
nositol 3-kinase catalytic subunit, PIK3CA, are specific for
HPV+ tumors, as they are not associated with Hepatitis
B or C liver cancers or HPV- oropharyngeal cancer and
are only found in cervical and HPV+ oropharyngeal can-
cers.[30] PIK3CA mutations are found in a variety of human
malignancies,[88] adding more evidence that HPV probably
causes many cancers. In addition, transition mutations C→T
(or G) in CDKN2A, a gene that codes for p16 and p14arf
tumor suppressor proteins are exclusive to HPV+ oropha-
ryngeal and cervical cancers.[89, 90] Intriguingly, many soft
tissue tumors have an amplicon from host genomic DNA
that HPV presumably deleted upon integration into chromo-
some 12q (12q13-15).[91] In this section of chromosome 12q,
many genes related to both cancer and HPV infection are
found: AID (12q13), APOBEC1 (12q13.1),[26] the vitamin
D receptor (12q13.11), CDK4 (cyclin-dependent kinases),
MDM2 (murine double minutes), SAS (sarcoma amplified
sequence),[26, 92] HMGI-C (high mobility glycoprotein), GLI
(Glioblastoma), CHOP(C/EBP Homologue Protein), OS4,
and OS9.[93] The vitamin D receptor has a large CpG is-
land in its promoter region so that it can be silenced by
methylation, which is important because it interacts with
coactivator and cosuppressor proteins that are in contact with
chromatin modifiers and remodelers and it also has certain
ligands that have DNA demethylating effects.[94] We can
obtain convincing evidence of an anticancer role for vitamin
D3 in humans from a recent vitamin D3, calcium random-
ized clinical trial using supplements,[95] along with a pooled
analysis of randomized trails,[96] and a prospective cohort
study[97] because they showed significant reductions in their
all-cancers risk. Intriguingly, Neanderthals gave some of the
Europeans HPV16A,[98] so that this ancestry population had
a “head start” for increasing their incidences of cancer over
recent decades from indoor work and decreasing levels of
vitamin D3.
Apparently, the “perfect storm” for creating cancer involves
76 ISSN 2377-9306 E-ISSN 2377-9330
http://jer.sciedupress.com Journal of Epidemiological Research 2017, Vol. 3, No. 2
high levels of estrogen, ROS (older age), and low vitamin D3
levels fueling persistent infection of immune-privileged an-
drogenic body hair by HPV, which is activated by ROS (red
and white hair) to release virions into the body increasing
viral loads over the advancing age of the individual.[16] De-
creasing vitamin D3 levels over recent decades has decreased
immune effectiveness[99–101] fueling HPV persistence, which
apparently contributes toward increasing the incidence of
many cancers. Our results provide worldwide evidence that
estrogen and old age (via ROS), rather than industrialized
chemical pollutants, plays major roles in most cancers and
suggests there may be even more HPV-related cancers than
previously thought. Increasing vitamin D3 levels and get-
ting the HPV vaccination may significantly decrease the
incidence of cancer in future generations.
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